US-EU trade

1 articles

The US–EU pharmaceutical tariff agreement reached last summer imposes a 15% tax on medicines imported from Europe and provides Section 232 exemptions for certain products. In the short term, it is expected to raise drug prices and insurance premiums; in the long term, it may trigger a restructuring of the supply chain.
Supply Chain

Will US–EU Pharma Tariffs Restore Domestic Production?

Will US–EU Pharma Tariffs Restore Domestic Production?